Cannabinoid regulation of neuromuscular transmission
Myasthenia gravis is a muscle weakness disease caused by autoimmune antibodies that impair synaptic transmission at the neuromuscular junction. Cannabinoid drugs influence the strength of synaptic transmission. This project will examine the pathways by which cannabinoids affect neuromuscular transmission and test their potential for treating myasthenia gravis in mouse models.
Myasthenia gravis is a chronic disease but the existing drugs used to treat it tend to lose their efficacy over time or carry with them potential harmful side effects for the patient.There is a need for new treatments for myasthenia gravis.Cannabinoids help to regulate quantal synaptic transmission in the central nervous system but their effects at the mammalian neuromuscular junction are not well understood. Our preliminary work suggests that cannabinoid drugs may have potential to enhance neuromuscular transmission in myasthenia gravis. This project will involve learning to make intracellular electrophysiological recordings to study the enhancing effects of cannabinoid drugs. Pharmacological blockers and cannabinoid-receptor knockout mice will then be used to identify the signalling pathways responsible for cannabinoid-mediated synaptic plasticity.The potential of cannabinoids to reverse muscle weakness will then be tested in mouse models of myasthenia gravis.
The lab is located within the Anderson Stuart Building (F13) with the excellent technical support of the Bosch Institute
Want to find out more?
Contact us to find out what’s involved in applying for a PhD.
Contact Research Expert to find out more about participating in this opportunity.
Browse for other opportunities within the Camperdown - School of Medical Sciences - Bosch Institute .
The opportunity ID for this research opportunity is: 1783
Other opportunities with Associate Professor William (Bill) Phillips